Delivery Order SPE2DP20D0002-SPE2DP25F109W
- Not listed
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $660,627.72 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on August 12, 2025, with an ultimate completion date of August 26, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents continued federal procurement from Teva as a critical supplier of vaccines and pharmaceutical products to military immunization programs. The contract will be performed at...
- The U.S. Department of Defense's Medical Supply Chain awarded a $660,627.72 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc. on September 8, 2025, for the supply of Adenovirus Type 4 vaccine. The contract, issued without set-aside designation, is scheduled for completion by September 23, 2025, with performance conducted at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of the Adenovirus...
- The U.S. Department of Defense's Medical Supply Chain division awarded a $1.16M firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of August 26, 2025. The contract, which carries no set-aside designation, will be performed at Teva's manufacturing facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of vaccines and pharmaceutical products to...
- The Defense Logistics Agency awarded Teva Pharmaceuticals USA, Inc. a firm fixed-price delivery order valued at $165,156.93 for Adenovirus Type 4 vaccine with an ultimate completion date of September 23, 2025. The contract, issued without a set-aside designation, is being performed in Parsippany, New Jersey, where Teva maintains its U.S. headquarters. This delivery order supports the Department of Defense's immunization programs and represents part of Teva's established role as a critical...
- Teva Pharmaceuticals USA, Inc. has been awarded a $1,526,969 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply adenovirus type 4 vaccine. This delivery order was issued under an existing contract vehicle and will support the immunization programs of the military. Teva will deliver the vaccine products to the agency's location in Parsippany, New Jersey by December 19, 2023. As a major pharmaceutical manufacturer, Teva has extensive experience...
- Teva Pharmaceuticals USA, Inc. has been awarded a $305,393.76 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to provide adenovirus type 4 vaccine. Performance will take place in Parsippany, New Jersey through December 2023. This delivery order was issued against an existing contract vehicle and supports the immunization programs of the military. Teva Pharmaceuticals has a history of partnering with subcontractors and receiving contract awards to supply...
- Teva Pharmaceuticals USA, Inc. has been awarded a $916,181 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply adenovirus type 4 vaccine. The delivery order was awarded on December 14, 2023 and is to be completed by December 19, 2023. Teva will provide the vaccine from its Parsippany, New Jersey location to support immunization programs of the Defense Logistics Agency Troop Support Medical. As the prime contractor, Teva has extensive experience...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Teva Pharmaceuticals USA, Inc., a pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. The contract has a firm fixed price of $282,353.76 and a completion date of February 23, 2021. The place of performance is Parsippany, New Jersey. Teva Pharmaceuticals USA, Inc. is a foreign-owned, for-profit organization that manufactures a range of drug products, including vaccines,...
- The U.S. Defense Logistics Agency Troop Support Medical awarded a Firm Fixed Price Delivery Order contract to Teva Pharmaceuticals USA, Inc. for the delivery of Adenovirus Type 4 vaccines. The $135,747.00 contract has an August 25, 2020 completion date. Teva Pharmaceuticals USA, Inc. is a foreign-owned, for-profit manufacturer that has provided a range of pharmaceutical products, including vaccines, antiviral medications, and respiratory treatments, to federal customers such as the Department of...
- Teva Pharmaceuticals USA, Inc. has been awarded a firm fixed price delivery order against the Defense Logistics Agency Troop Support Medical for $2,443,150.08 to supply adenovirus type 4 vaccine. The place of performance is Parsippany, New Jersey and the completion date is December 19, 2023. This delivery order supports the military immunization programs of the Defense Logistics Agency Troop Support Medical by providing the requested adenovirus type 4 vaccine. Teva Pharmaceuticals USA, Inc. is a...
- SPE2DP20D0002Indefinite Delivery Contract
- SPE2DP20D0002-SPE2DP25F109WDelivery Order
The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and represents part of the Defense Logistics Agency Troop Support Medical's ongoing pharmaceutical supply chain for military immunization programs. Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd. and a major federal pharmaceutical supplier, serves as the prime contractor on this award. The company has established itself as a critical vendor to the Department of Defense and other federal healthcare agencies through its consistent delivery of essential pharmaceutical products, including vaccines and antiviral medications. This contract award demonstrates Teva's capability to supply high-volume medical products with precision and supports the Department of Defense's immunization requirements for military personnel.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $825.8k | 9/8/25 |